Pharmaceutical Technology

AUGUST 8, 2023

Pricing and reimbursement of pharmaceuticals is changing in Sweden, with prices lower than average as a result of growing cost containment strategies. Here’s what you need to know.

Marketing 130

Marketing Containment 130

pharmaphorum

APRIL 30, 2021

It’s fair to say this is the most interesting time ever for market access. A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how they can find a smoother path to market. Rethinking access barriers to innovation.

Marketing 98

Marketing Sales Regulation Drugs 98

XTalks

MAY 11, 2023

This makes it crucial that we adopt systems that make our webinars accessible to the greatest proportion of the population. Webinar hosts dedicate a lot of time and effort when creating webinar content, marketing it to potential attendees and practicing the delivery to ensure they convey their message to the audience in the best way possible.

Marketing 98

Marketing Production Life Science Regulation 98

Drug Channels

NOVEMBER 10, 2023

Today’s guest post comes from James Pisano, Partner, Market Access at The Dedham Group and Dinesh Kabaleeswaran, SVP of Insights & Advisory Teams at MMIT. James and Dinesh offer four trends that they predict will shape medication access in the coming years.

Marketing 75

Marketing Drugs 75

Intouch Solutions

JULY 26, 2023

Payer marketing, reimbursement strategy, payer engagement, market access – whatever term your organization might use, optimizing your brand value and communicating that value to your stakeholders is a vital discipline. Download POV

Marketing 52

Marketing Branding Research 52

Intouch Solutions

JULY 26, 2023

Payer marketing, reimbursement strategy, payer engagement, market access – whatever term your organization might use, optimizing your brand value and communicating that value to your stakeholders is a vital discipline. Download POV

Marketing 52

Marketing Branding Research 52

pharmaphorum

MAY 31, 2023

PM Society’s ‘Securing Market Access to Medicines for England, Ireland, Scotland & Wales’ – part one Mike.Hammerton Wed, 05/31/2023 - 12:45 Bookmark this

Medicine 97

Medicine Marketing 97

pharmaphorum

FEBRUARY 24, 2021

2021 will be the year when big market access changes – including the far wider use of health economic evaluation – are implemented in Spain. In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring for market access in Spain.

Marketing 99

Marketing Pharmacy Medicine Branding 99

Drug Discovery World

FEBRUARY 28, 2023

A new strategic guide , intended to help manufacturers bring rare disease products to market, has been launched to mark Rare Disease Day (February 28). Craig Caceci, Terebellum’s Managing Director, commented: “Bringing any product to market, particularly those used to treat rare and orphan diseases is a challenge enough.

Marketing 52

Marketing Production Manufacturing Drugs 52

Drug Channels

MARCH 28, 2024

Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Today’s guest post comes from Bill Dupere, SVP of Product Development & Partnerships at Mercalis. Contact Mercalis to learn about their Patient Support Services. Read on for Bill’s insights.

Life Science 81

Life Science Marketing Production Development 81

pharmaphorum

MARCH 1, 2021

In the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes stock of what 2021 could bring for market access in France. The draft includes simplification of early access to new medicines aiming to make access faster and more attractive to companies. About the author.

Marketing 78

Marketing Medicine Branding Development 78

pharmaphorum

MAY 6, 2022

For life science companies around the world, enabling faster access to innovative drugs and therapies is a complicated challenge. Combination pricing: access to the future of oncology treatment. Read Deep Dive: Market Access in full. The post Deep Dive: Market Access appeared first on.

Marketing 52

Marketing Life Science Regulation Development 52

pharmaphorum

FEBRUARY 23, 2021

The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and what needs reform. The AMNOG (Act on the Reform of the Market for Medicinal Products) was implemented on the 1 January 2011.

Marketing 89

Marketing Medicine Gene Therapy Drugs 89

Drug Channels

OCTOBER 8, 2021

Today’s guest post comes from Bill Dupere, Practice Lead and VP of Market Access Solutions and Eric Willis, VP of Operations Hub and Reimbursement Services at TrialCard. Bill and Eric discuss the complexities of digital patient support program technologies and introduce TrialCard’s integrated suite of solutions.

Marketing 90

Marketing Pharmacy Sales Drugs 90

Bio Pharma Dive

APRIL 13, 2023

The order is the latest twist in an escalating legal battle over access to mifepristone, a fight that is headed to the Supreme Court.

Marketing 177

Marketing Drugs 177

Intouch Solutions

SEPTEMBER 28, 2021

Addition of New Affiliate Positions Firm to Drive Value and Access. OVERLAND PARK, KS (September 24, 2021) – Intouch Group, a full-service global agency network serving the pharmaceutical industry, today announced the addition of Intouch Market Access as its eighth affiliate to address the ever-evolving needs of clients.

Marketing 52

Marketing Life Science Branding Manufacturing 52

pharmaphorum

APRIL 1, 2022

However, while this dramatic shake-up of the UK Market Access environment aims to improve care for patients and providers for life science companies, this unfamiliar territory presents both opportunities and challenges. The post ICSs – an opportunity to improve Patient & Market Access at a local level appeared first on.

Marketing 98

Marketing Life Science Pharmacy Sales 98

Intouch Solutions

SEPTEMBER 28, 2021

Fast forward two years, and you’ll see that these access issues haven’t changed. At Intouch Group, we’ve been providing thought leadership and helping our clients work proactively to address affordability and access issues for years. Why Intouch Market Access? Further, U.S. In a word, experience.

Marketing 52

Marketing Drugs Medicine 52

pharmaphorum

JUNE 21, 2022

Whether it’s the levelling up agenda, economics, social care and population health management and more, ICSs are front and centre of everything,” Steven Ferguson, head of Market Access UK and Ireland, IQVIA. The post ICSs: improving patient and market access at a local level appeared first on.

Marketing 52

Marketing Life Science 52

pharmaphorum

MAY 5, 2023

Securing Market Access to Medicines for England, Ireland, Scotland Wales – The Landscape Ahead Mike.Hammerton Fri, 05/05/2023 - 07:20 Bookmark this

Medicine 52

Medicine Marketing 52

pharmaphorum

JUNE 8, 2022

The move marks the largest expansion of FH to date and allows clients to benefit from integrated offerings spanning policy, access, value, and evidence. The addition of Avalere’s more than 200 advisors deepens FH’s US market presence and diversifies its customer base. We are excited to welcome Avalere to FH.” .

Marketing 52

Marketing Life Science Production Regulation 52

pharmaphorum

AUGUST 17, 2023

War in the Blood: The battle takes shape in the burgeoning European oncology CAR-T market access space Mike.Hammerton Thu, 17/08/2023 - 09:00 Bookmark this

Marketing 52

Marketing 52

Intouch Solutions

FEBRUARY 4, 2021

The post Brand & Market Access Leaders, Your Time Is Now appeared first on Intouch Solutions. New administration, new approach to healthcare: the old playbook isn't enough anymore. Is your pharma brand ready to optimize patient, caregiver, and HCP experiences in this evolving landscape?

Branding 52

Branding Marketing 52

Pharmaceutical Commerce

OCTOBER 5, 2022

Wednesday, October 5, 2022, 11am EDT Market access considerations can be complex to navigate and overwhelming to address for biopharmaceutical commercial teams launching their first specialty drug. Get answers to eleven key questions that will help guide commercial teams in effectively launching specialty products.

Marketing 52

Marketing Drugs Production 52

pharmaphorum

AUGUST 25, 2021

Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute Remdesivir. Government partnerships are crucial to accessibility.

Marketing 52

Marketing Licensing Licensing Manufacturing 52

Pharmaceutical Technology

APRIL 19, 2024

The long-term agreement will see increased access of Simlandi, a biosimilar to AbbVie’s Humira, in the US market.

Marketing 130

Marketing 130

BioTech 365

AUGUST 30, 2021

Indegene strengthens its Pricing, Reimbursement and Market Access capabilities with Medical Marketing Economics, LLC acquisition Indegene strengthens its Pricing, Reimbursement and Market Access capabilities with Medical Marketing Economics, LLC acquisition PRINCETON, N.J.,

Marketing 40

Marketing 40

BioTech 365

NOVEMBER 3, 2021

AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access UTRECHT, The Netherlands–(BUSINESS WIRE)–AM-Pharma B.V.,

Marketing 40

Marketing Development 40

Pharmaceutical Technology

DECEMBER 15, 2022

France’s temporary authorisation system (autorisation temporaire d’utilisation, ATU) was developed to provide early market access for treatments in therapeutic areas with unmet medical need, limited therapeutic alternatives, or where no authorised alternatives are available.

Medicine 147

Medicine Marketing Drugs Branding 147

pharmaphorum

JUNE 12, 2017

Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans.

Marketing 52

Marketing Life Science Engineer Branding 52

Drug Channels

APRIL 4, 2023

Four crucial trends will deflate the gross-to-net bubble—thereby disrupting market access strategies, altering pharmacy benefit manager (PBM) profit models, and changing plan sponsor benefit designs. Our latest data appear below. Perhaps it’s time to get ready for the day when SpongeBob SquarePants will depart from Drug Channels.

Marketing 58

Marketing Branding Sales Pharmacy 58

Drug Channels

JUNE 21, 2023

Four crucial trends will deflate the gross-to-net bubble—thereby disrupting market access strategies, altering pharmacy benefit manager (PBM) profit models, and changing plan sponsor benefit designs. Our latest data appear below. Perhaps it’s time to get ready for the day when SpongeBob SquarePants will depart from Drug Channels.

Marketing 61

Marketing Branding Sales Pharmacy 61

pharmaphorum

FEBRUARY 19, 2021

Ashfield Advisory , part of UDG Healthcare plc, today announced the acquisition of PHMR Limited, a Market Access Consultancy and specialist in Health Economics and Outcomes Research (HEOR). The post UDG Healthcare acquires market access, HEOR specialist, PHMR Limited as Ashfield Advisory appeared first on.

Marketing 52

Marketing Scientist Research 52

Drug Patent Watch

JANUARY 21, 2021

The post Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions appeared first on DrugPatentWatch - Make Better Decisions. Highlights….

Gene Therapy 52

Gene Therapy Gene Marketing Licensing 52

BioTech 365

APRIL 8, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bannister joins SVB to help companies raise cash, access public markets.Bannister joins SVB to help companies raise cash, access public markets ntaylor Thu, 04/08/2021 – 08:17 from … Continue reading →

Marketing 40

Marketing Research 40

BioTech 365

NOVEMBER 18, 2020

Global Biosimilars Market 2020-2026: Access to New Therapy Areas to Drive Major Growth – ResearchAndMarkets.com Global Biosimilars Market 2020-2026: Access to New Therapy Areas to Drive Major Growth – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global Biosimilars Market 2020-2026: Access to New Therapy … Continue (..)

Marketing 40

Marketing 40

BioTech 365

DECEMBER 18, 2020

Global Real World Evidence (RWE) Solutions Markets, 2020-2027: Drug Development and Approvals (Oncology, Neurology, Immunology), Market Access, Medical Device Development – ResearchAndMarkets.com Global Real World Evidence (RWE) Solutions Markets, 2020-2027: Drug Development and Approvals (Oncology, Neurology, Immunology), Market Access, Medical (..)

Marketing 40

Marketing Development Drugs 40